other material
confidence high
sentiment positive
materiality 0.55
ZEO ScientifiX positioned for Florida stem cell market growth after SB 1768 enactment
Zeo ScientifiX, Inc.
- Florida SB 1768, effective July 1, 2025, allows physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain under cGMP.
- ZEO expects revenue growth from increased physician demand, patient awareness, and medical tourism to Florida.
- Company launched IRB-approved clinical study (PPX™) for musculoskeletal joint pathologies, targeting up to 350 patients; 5 clinics enrolled, 7 patients to date.
- ZEO evaluating lab expansion at Nova Southeastern University for additional clean rooms and research space.
- New law enables collection of real-world safety/outcome data, potentially lowering risks for future FDA submissions.